Amgen is opening a new affiliate in Argentina this year to further support making its high-quality, innovative therapies for the treatment of serious illnesses available to patients in Argentina, the Company announced on March 22.
A worldwide leader in human therapeutics research and development and biologics manufacturing, Amgen has an outstanding track record of delivering high-quality innovative medicines to patients who need them. Amgen is committed to improving access to medicines and the sustainability of healthcare systems around the globe, and for this reason is developing a robust portfolio of high-quality biosimilar medicines, which it intends to make available in Argentina, alongside its portfolio of innovative medicines.
Amgen’s entry into Argentina is an important step in the Company’s ongoing international expansion effort. Today it has operations in approximately 100 countries and regions around the world, and has medicines on the market in 11 countries in Latin America. Amgen’s medicines are currently available in Argentina through local distributors.
“We are excited to be establishing an affiliate in Argentina, where abundant resources are invested in the biotechnology industry, and where the government has stated its interest in cultivating the industry,” said Cristian Videla, who was recently appointed general manager of Amgen’s Argentina affiliate.
Amgen has had an R&D presence in Argentina for the past 10 years, having invested in approximately 30 clinical trials in the country over the last decade, with nearly 2400 patients enrolled over the past decade at more than 300 clinical sites. Amgen’s newest affiliate will be headquartered in Buenos Aires.